Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Advanced unresectable hepatocellular carcinoma confirmed by histology or cytology * Age 20-79 * At least one measurable lesion defined in RECIST version 1.1 * Child Pugh grade B * ECOG PS score 2 * The expected life is at least 90 days Exclusion Criteria: * Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any other treatment that regulates T cells * Received systemic corticosteroid or immunosuppressive therapy within 28 days before enrollment * Complicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseases * History of pleural or pericardial adhesions within 28 days before enrollment * HIV antibody, HTV-Ⅰantibody, HCV antibody, hepatitis B surface protein antigen, hepatitis B surface protein antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA test results were positive * Multiple primary cancers (excluding completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years) * Brain or meningeal metastasis (unless asymptomatic and does not require treatment) * Uncontrollable or serious cardiovascular disease.